Beta Drugs Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 17, 2026
- Posted by: Harsh Piplani
- Category: Results
Beta Drugs share price Rs 2,075.80 on 17 September 2026, up 0.53%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 16.00 crore. Q2 FY26 base a profit of Rs 12.00 crore.
Quick Answer
The Beta Drugs Q2 results date for FY27 is not confirmed, and Beta Drugs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 103.00 crore in revenue and a profit of Rs 12.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Beta Drugs Q2 results FY27 announcement is the next scheduled earnings event for Beta Drugs Ltd., Beta Drugs Ltd is an Indian pharmaceutical company that manufactures and markets oncology and other specialty injectable formulations for domestic and export markets.. The stock traded at Rs 2,075.80 on the NSE on 17 September 2026, up 0.53% from the previous close of Rs 2,064.90, about 26.1% below its 52-week high of Rs 2,807.90 and 109.7% above its 52-week low of Rs 990.10.
What makes the Beta Drugs Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 103.00 crore of revenue and a profit of Rs 12.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 126.00 crore and a profit of Rs 16.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Beta Drugs Q2 Results FY27 Date?
The Beta Drugs Q2 results date for FY27 is not confirmed. As of 17 September 2026, Beta Drugs Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
Also read – India Glycols Q2 Results FY27 Preview: Results Date, Expectations
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Beta Drugs Q2 results date becomes public through that filing rather than through any advance announcement.
The Beta Drugs Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Beta Drugs.
Beta Drugs Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Beta Drugs Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Beta Drugs. The Beta Drugs Q2 results watchlist below is built from what the company has actually reported and disclosed.
Beta Drugs Q2 results are coming up as the company heads into the September 2026 quarter on the back of a fairly steady run of numbers. Revenue has grown from Rs 100 crore in Jun25 to Rs 103 crore in Sep25, dipped slightly to Rs 87 crore in Dec25, recovered to Rs 94 crore in Mar26, and then jumped to Rs 126 crore in Jun26, the strongest quarter of the five shown. That gradual improvement, rather than any dramatic swing, is the backdrop against which Beta Drugs Q2 results will be measured this time.
Profitability has tracked revenue closely. Operating margin has stayed in a tight band, from 20% in Jun25 to 21% in Sep25, 19% in both Dec25 and Mar26, and 22% in Jun26, while net profit moved from Rs 12 crore in Jun25 and Sep25 down to Rs 9 crore in Dec25 and Mar26 before rising to Rs 16 crore in Jun26. With ROE at 18.8% and ROCE at 19.2%, the return profile looks reasonably healthy on a trailing basis, and consistency rather than volatility has been the theme heading into Beta Drugs Q2 results this cycle.
Also read – Gujarat Fluorochemicals Q2 FY27 Preview: Revenue, Margin & Profit Trend
Because the recent trend has been one of steady, incremental improvement rather than sharp swings, expectations for Beta Drugs Q2 results in the September 2026 quarter can reasonably be anchored to this pattern of gradual growth in revenue and margin. The company has also not paid a dividend despite consistent profitability, which suggests profits are being retained rather than distributed. None of this guarantees a particular outcome, but the underlying trend gives a more stable base for Beta Drugs Q2 results than companies with more erratic quarterly histories.
Check Beta Drugs Ltd. Live Fundamentals on the Univest Screener
Beta Drugs Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Beta Drugs Ltd. reported revenue of Rs 126.00 crore in Q1 FY27, up 26.00% from Rs 100.00 crore in Q1 FY26, and a profit of Rs 16.00 crore at the net level, up 33.33% from Rs 12.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 34.04% over the March 2026 quarter figure of Rs 94.00 crore, and net profit was up 77.78% from Rs 9.00 crore in Q4 FY26. Operating margin stood at 20.0% in Q1 FY27 against 21.0% in the September 2025 quarter, which is the comparison the Beta Drugs Q2 results print will be read against.
Q2 FY26 Base: The Comparison Beta Drugs Q2 Results FY27 Must Beat
Beta Drugs Ltd. reported revenue of Rs 103.00 crore and a profit of Rs 12.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Beta Drugs Q2 results preview.
Net profit in that base quarter was below the Rs 16.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 103.00 crore sits below the Rs 126.00 crore of the June 2026 quarter, which frames how much sequential movement the Beta Drugs Q2 results print needs to show growth.
Beta Drugs Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 103.00 | 12.00 |
| Q3 FY26 (Dec 2025) | 87.00 | 9.00 |
| Q4 FY26 (Mar 2026) | 94.00 | 9.00 |
| Q1 FY27 (Jun 2026) | 126.00 | 16.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Beta Drugs Q2 results preview uses.
Revenue across those four quarters ranged from Rs 87.00 crore to Rs 126.00 crore, and net profit from Rs 9.00 crore to Rs 16.00 crore. That spread is the honest context for the Beta Drugs Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Beta Drugs Q2 Results FY27
The Beta Drugs Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Beta Drugs has already reported.
Consistent Revenue Growth
One of the clearer factors behind Beta Drugs Q2 results is the steady upward drift in revenue over the last five quarters, culminating in the Jun26 figure of Rs 126 crore. Unlike businesses with sharp quarter-to-quarter reversals, this pharmaceutical formulations maker has shown a more gradual build, which tends to make near-term expectations easier to frame.
Stable Margins
Operating margin has stayed within a narrow 19% to 22% range across the last five quarters, and that stability is a meaningful input into how Beta Drugs Q2 results are likely to be read by the market. A margin base this consistent leaves less room for a surprise swing compared with companies whose margins move by many percentage points each quarter.
No Dividend Despite Profits
Beta Drugs has not paid a dividend even though it has remained profitable in every one of the last five quarters, with ROE at 18.8% and ROCE at 19.2%. That choice to retain earnings rather than distribute them is a factor some investors will weigh alongside Beta Drugs Q2 results, since it points to a company prioritising reinvestment over payouts at this stage.
Beta Drugs Q2 Results FY27: Share Price and Valuation Going Into the Print
Beta Drugs share price today is Rs 2,075.80 on the NSE, up Rs 10.90 or 0.53% from the previous close of Rs 2,064.90 on 17 September 2026, ahead of the Beta Drugs Q2 results announcement.
| Metric | Value (17 September 2026) |
|---|---|
| NSE Symbol | BETA |
| Current Market Price | Rs 2,075.80 |
| 52-Week High | Rs 2,807.90 |
| 52-Week Low | Rs 990.10 |
| Market Capitalisation | Rs 2301 crore |
| PE Ratio | 50.46 |
| PB Ratio | 8.61 |
| EPS (TTM) | Rs 41.14 |
| Book Value per Share | Rs 241.00 |
| Debt to Equity | 0.60 |
| Return on Equity | 18.8% |
| 50-Day Moving Average | Rs 2293.23 |
| 200-Day Moving Average | Rs 1673.60 |
| RSI (14) | 40.34 |
The stock trades below its 50-day average of Rs 2293.23 but above its 200-day average of Rs 1673.60, with a 14-day RSI of 40.34. None of this is a view on where the shares go once the Beta Drugs Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Beta Drugs Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Beta Drugs Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Beta Drugs Q2 results print in proportion.
- Revenue against the Rs 103.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 12.00 crore in that same quarter
- Operating margin against 20.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Beta Drugs Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Beta Drugs Q2 Results FY27
The Beta Drugs Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Beta Drugs Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Beta Drugs Q2 results FY27 print faces a base of Rs 103.00 crore in revenue and a profit of Rs 12.00 crore, with the most recent quarter having delivered Rs 126.00 crore and a profit of Rs 16.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Beta Drugs, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Beta Drugs Q2 Results FY27
What is the Beta Drugs Q2 results date for FY27?
Ans. The Beta Drugs Q2 results date for FY27 is not confirmed. Beta Drugs Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Beta Drugs Q2 results 2026 cover?
Ans. The Beta Drugs Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Beta Drugs Ltd. reports revenue, operating profit and net profit for that period, and the Beta Drugs Q2 results filing also carries the notes to the accounts.
What were the Beta Drugs Q1 FY27 results?
Ans. Beta Drugs Ltd. reported revenue of Rs 126.00 crore in Q1 FY27 and a profit of Rs 16.00 crore at the net level. Revenue was up 26.00% versus Q1 FY26 and net profit was up 33.33% from Rs 12.00 crore in Q1 FY26.
What were Beta Drugs Q2 FY26 results in the September 2025 quarter?
Ans. Beta Drugs Ltd. reported revenue of Rs 103.00 crore and a profit of Rs 12.00 crore in Q2 FY26. Operating margin was 21.0%. Those figures form the base for the Beta Drugs Q2 results FY27 comparison.
What are the main Beta Drugs Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Beta Drugs Q2 results expectations centre on revenue against the Rs 103.00 crore base, net profit against a profit of Rs 12.00 crore, operating margin against 20.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Beta Drugs share price today ahead of the Q2 earnings?
Ans. Beta Drugs share price is Rs 2,075.80 on the NSE as of 17 September 2026, up 0.53% from Rs 2,064.90. The stock is about 26.1% below its 52-week high of Rs 2,807.90 and 109.7% above its 52-week low of Rs 990.10, at a market capitalisation of Rs 2301 crore.
Is Beta Drugs a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Beta Drugs Ltd. The stock trades at a price-to-book ratio of 8.61 with a return on equity of 18.8%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
